Earnings ·
Ultragenyx Pharmaceutical Inc. reported second quarter 2026 financial results with total revenue of $214 million, up…
RAREUltragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. reported second quarter 2026 financial results with total revenue of $214 million, up from $167 million in the prior year period. Crysvita generated $156 million and Dojolvi contributed $27 million. The company reaffirmed its full-year 2026 guidance for total revenue between $730 million and $760 million and combined R&D and SG&A expenses to be flat or slightly down versus 2025. Net loss narrowed to $92 million, or $0.90 per share, compared to a net loss of $115 million in the same quarter last year. Cash, cash equivalents, and marketable securities stood at $436 million as of June 30, 2026. The company highlighted upcoming catalysts including PDUFA dates for DTX401 on August 23, 2026, and UX111 on September 19, 2026, alongside pivotal data readouts for GTX-102 in Angelman syndrome. Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases.